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Allergy and autoimmunity result from dysregulation of the immune system. Until recently, it was
generally accepted that the mechanisms that govern these disease processes are quite disparate;
however, new discoveries suggest possible common pathogenetic effector pathways. This review
illustrates the concomitant presentation of these conditions and the potential relationship or common
mechanism in some cases, by looking at the key elements that regulate the immune response in both
allergic and autoimmunite conditions: mast cells, antibodies, T cells, cytokines, and genetic
determinants. The parallel appearance of allergic and autoimmune conditions in the some patients may
reveal that such aberrations of the immune system have a common pathophysiologic mechanism. Mast
cells, whichplay akeyrolein allergic reactions, and thewealth ofinﬂammatory mediators they express,
make it likely that they have profound effects on many autoimmune processes. Activation of protein
kinases by inﬂammatory cytokines and environmental stresses may contribute to both allergic and
autoimmune diseases. The presence of autoantibodies in some allergic conditions suggests an
autoimmune basis forthese conditions. Because of the central role T cells play in immune reactivity, the
T-cell receptor (TCR) loci have long been considered important candidates for common disease
susceptibility within the immune system such as asthma, atopy, and autoimmunity. Immunomodulation
is the key to a successful treatment of allergic and autoimmune conditions.
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INTRODUCTION
Malfunction of the immune system is known in three main
conditions: immunodeﬁciency, allergy, and autoimmunity.
These states usually appear separately. Two of the
conditions, immunodeﬁciency and autoimmunity, some-
time appear together, such as autoimmunity in IgA
deﬁciency or in common variable immunodeﬁciency. The
appearance of autoimmunity and allergies has not been
well appreciated. Recently, there are reports on the
appearance of allergies concomitantly with autoimmunity,
but the relationship is poorly understood. Allergy and
autoimmunity are two potential outcomes of dysregulated
immunity. Both are characterized by localized inﬂam-
mation that leads to the injury and/or destruction of target
tissues. Until recently, it was generally accepted that the
mechanisms that govern these disease processes are quite
disparate; however, new discoveries suggest possible
pathogenetic linkage. In this review we shall summarize
and discuss the concomitant presentation of these
conditions and the potential relationship or common
mechanism, and we will do so by looking at the key
elements that regulate the immune response in allergy and
autoimmunity.
MAST CELLS IN ALLERGIC AND AUTOIMMUNE
DISEASES
Mast cells are distributed widely throughout mammalian
tissues, especially the perivascular spaces and connective
tissues in the skin, respiratory and gastrointestinal tracts.
Cross-linkage of the high afﬁnity IgE receptors elicits the
release of preformed granules including histamine, neutral
proteases, cytokines and proteoglycans (Stevens and
Austen, 1989). There is also a rapid synthesis and release
of prostaglanduns and leukotriens. Activated mast cells
also synthesize and secrete several proinﬂammatory,
chemoattractive, and immunomodulatory cytokines over a
period of several hours. While the role of mast cells in
allergic diseases is well recognized, it was not until
recently that knowledge has been gathered on their
physiologic role and their role in non-allergic diseases and
non-IgE mediated stimuli (Stevens and Austen, 1989).
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There is a prominence of lesional mast cells in multiple
sclerosis, (MS) (Ibrahim et al., 1996), cardiomyopathy
(Arbustini et al., 1997), congestive heart failure (Hara
et al., 2002), rheumatoid arthritis, (RA) (Gotis-Graham
and McNeil, 1997; Woolley and Tetlow, 2000; Lee et al.,
2002), liver disease (Matsunaga et al., 1999), and ﬁbrotic
lung conditions (Pesci et al., 1993). Previous studies have
revealed that autoantibodies, complement components,
and Fc receptors each participate in the pathogenesis of
erosive arthritis in K=B £ N mice. However, it is not
known which cellular populations are responsive to these
inﬂammatory signals. Two strains of mice deﬁcient in
mast cells, W/W
v and Sl/Sl
d, are resistant to development
of joint inﬂammation and susceptibility is restored in the
W/W
v strain by mast cell engraftment. Thus, mast cells
may function as a cellular link between autoantibodies,
soluble mediators, and other effector populations in
inﬂammatory arthritis (Lee et al., 2002). Mast cell-
deﬁcient mice exhibit signiﬁcantly reduced disease
severity compared to wild-type littermates in a murine
model of MS and drugs that block mast cell function can
improve clinical symptoms in this model. In addition,
gene microarray analysis has revealed that the expression
of several mast cell-speciﬁc genes is increased in the
central nervous system plaques of MS patients. Although
well established as effector cells in allergic inﬂammation,
the location of mast cells and the wealth of inﬂammatory
mediators they express make it likely that they have
profound effects on many other autoimmune processes
(Robbie-Ryan and Brown, 2002).
AUTOANTIBODIES IN ALLERGIC AND
AUTOIMMUNE DISEASES
The allergic response to common environmental allergens
has been regarded as an important mechanism in the
development of airway inﬂammation of patients with
asthma. The idea of a possible involvement of
autoimmunity in the pathogenesis of non-allergic asthma
has been proposed by few studies (Lidor et al., 1980).
Atopicindividualswithasthma,allergicrhinitisoratopic
eczema have impaired sensitivity to beta-adrenergic
agents. Antibodies directed toward the beta adrenergic
receptor were found in sera of some patients with asthma
(Harrison et al., 1982) suggesting that autoantibodies to
beta-receptors play a pathogenetic role in asthma and
related disorders. The serum gamma-globulin fraction
from patients with allergic bronchial asthma was found to
inhibit the positive chronotropic action of the beta
2-selectiveadrenergicagonist,butnotofbeta 1-adrenergic
agonist(WallukatandWollenberger,1991).Theinhibitory
immunoglobulins of the patients with asthma were mainly
autoantibodiesoftheIgGisotype,capableofcross-reacting
with chronotropic beta 2-adrenergic receptors on the
cultured rat cardiomyocytes. These ﬁndings provide
support for the notion that autoimmunity plays a role in
the impairment of beta-adrenergic responsiveness in
patients with allergic bronchial asthma. Similar studies
were performed to reveal the role of antibodies on
bronchial epithelium. Serum samples from healthy
controls, patients with atopic asthma, patients with non-
atopic asthma, and patients with systemic lupus erythema-
tosus were studied for the presence of circulating
autoantibodies to cultured human bronchial epithelial cell
using enzyme-linked immunosorbent assay (Nahm et al.,
2001). Levels of IgG autoantibodies to bronchial epithelial
cell were signiﬁcantly higher in patients with non-atopic
asthma and systemic lupus erythematosus than in healthy
controls and patients with atopic asthma. These circulating
IgG autoantibodies were further studied by immunoblot
analysis (Nahm et al., 2002). IgG autoantibodies to the
49-kD bronchial epithelial cell antigen were detected in
43% of patients with non-allergic, 11% of patients with
allergic asthma, 10% of patients with systemic lupus
erythematosus, and 9% healthy volunteers ðP , 0:005Þ:
The 49-kD auto-antigen was puriﬁed and identiﬁed as
cytokeratin 18 by amino acid sequencing. In this study
cytokeratin 18 was identiﬁed as a bronchial epithelial
autoantigen associated with non-allergic asthma. Taken
together, the presence of autoantibodies to beta adrenergic
receptors and bronchial epithelium in patients with atopic
and non-atopic asthma, respectively, demonstrate auto-
immune phenomena in these conditions.
Patients suffering from atopic dermatitis (AD) fre-
quently display IgE autoantibody reactivity to human
proteins expressed in cell lines of different histogenetic
origins. Molecular cloning and in situ staining experi-
mentsrevealed that certain IgE-reactive autoantigens were
expressed preferentially in target organs of atopy while
others could be detected in various tissues and cell types
(Seiberler et al., 1999). Serum IgE from AD patients was
used to investigate the distribution of autoantigens in
subcellular fractions of the human epithelial cell line
A431 and in human tissue specimens. Results showed that
IgE-reactive autoantigens can be detected in the nuclear .
microsomal . mitochondrial . cytoplasmic fraction of
A431 cells as well as in a variety of human tissue
specimens (brain, bone, intestine, liver, lung, muscle, skin,
uterus) and effector cells of atopy (basophils, mast cells,
T cells). If IgE autoreactivity plays a pathogenetic role in
severe forms of atopy, organ-speciﬁc manifestations (e.g.
AD) may result from the transport to and deposition of
IgE-reactive autoantigens in certain target organs (skin)
rather than from a preferential expression of the
autoantigens in the affected tissues.
Schnitzler’s syndrome is a rare disease characterized by
chronic urticaria, monoclonal IgM, and clinical and
laboratory signs of inﬂammation. In a subset of patients,
the urticarial lesions cause pruritus. However, the
pathophysiology of the disease and the biochemical basis
of urticaria are not known. Sperr et al. (2000) described a
subclass-speciﬁc IgG reactivity against microvascular
endothelial cells and mast cells indicating Th1 auto-
immunity in a patient with Schnitzler’s syndrome.
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patients with Schnitzler’s syndrome and play a role in the
pathophysiology of the disease remains to be determined.
Szczeklik et al. (1995) assessed the autoimmune status
of 185 adult patients with bronchial asthma and 46 healthy
subjects of similar sex and age. The patients were divided
into groups with: aspirin-induced asthma (AIA), intrinsic
asthma with good aspirin tolerance, and atopic asthma.
Antinuclear antibodies (ANA) at a titer of . or ¼ 1:40
were present in the serum of 55% of the patients with AIA,
41% of those with intrinsic asthma, 39% of those with
atopic asthma, and 11% of the healthy subjects, with the
difference between each patient group and the healthy
subjects being statistically signiﬁcant ðP , 0:05Þ: The
ﬂuorescence staining pattern of ANA on Hep-2 cells was
mainly speckled, but the precise antigen speciﬁcity of the
antibodies could not be identiﬁed with reference sera
against extractable nuclear antigens. None of the subjects
exhibited anti-double stranded deoxyribonucleic acid
(anti-ds-DNA) or anti-neutrophil cytoplasmic antibodies
(ANCA). Positive ANA were associated with signs of
complement activation, the presence of rheumatoid factor,
and circulating immune complexes. Clinical signs of
autoimmunity, evidenced by rheumatic symptoms, cold
sensitivity, and Raynaud’s phenomenon, were more
common among the patients who tested positively for
ANA. These results should, however, be interpreted
cautiously, since ANA positivity in 1:40 dilution can be
found in a signiﬁcant number of healthy individuals (Tan
et al., 1997). Based on 15 international laboratories
experienced in performing ANA tests, Tan et al. revealed
that the normal population was ANA positive in 31.7%
of individuals at 1:40 serum dilution, 13.3% at 1:80, 5.0%
at 1:160, and 3.3% at 1:320. They concluded that it is
recommended thatlaboratories performingimmunoﬂuore-
scent ANA tests should report results at both the 1:40 and
1:160 dilutions, and should supply information on the
percentage of normal individuals who are positive at these
dilutions. A low-titer ANA is not necessarily insigniﬁcant.
ANA assays can be a useful discriminant in recognizing
certain disease conditions, but can create misunderstand-
ing when the limitations are not fully appreciated. The
assessment of autoimmunity may help in better character-
izing patients with asthma and understanding various
symptoms of the disease. Any causal relationship between
asthma and autoimmunity remains to be established.
T-CELL DYSREGULATION IN ALLERGIC AND
AUTOIMMUNE DISEASES
Regulatory T cells (also referred to as suppressor T cells)
are important components of the homeostasis of the
immune system, as impaired regulatory T cell activity can
cause autoimmune diseases and atopy. CD8þ T cells are
known to mediate delayed-type hypersensitivity (DTH)
responses in allergic contact dermatitis, drug eruptions,
asthma, and autoimmune diseases. DTH is deﬁned as
the recruitment of T cells into tissues to be activated by
antigen-presenting cells to produce cytokines that mediate
local inﬂammation. This inﬂammatory effector capability
of CD8þ cytotoxic T cells was previously poorly
recognized, but there is now considerable evidence that
inﬂammatory diseases may be mediated by CD8þ DTH
(Kalish and Askenase, 1999).
Thecauseofasthma,whichhasbeenlinkedtoachronic,
T-cell-mediated bronchial inﬂammation, remains unclear.
AnumberofotherT-lymphocyte-mediated,chronicinﬂam-
matory disorders have been associated with autoimmunity
and there are data indicating that autoimmune phenomena
might alsobepresent inasthma.Arnold etal.(2000) tested
the hypothesis that allergic and intrinsic asthma might be
associated with an increase in lymphocytes producing
perforin, a cytotoxic molecule produced by lymphocytes
thathasbeenimplicatedinthepathogenesisofautoimmune
diseases, by comparing the expression of intracellular
perforin in peripheral blood lymphocytes of patients with
extrinsicasthmacomparedtopatientswithintrinsicasthma
and healthy control subjects. The percentage of perforin-
positive total lymphocytes was signiﬁcantly elevated in
patients with allergic as well as intrinsic asthma when
compared with normal control subjects. Analysis of
lymphocyte subpopulations also revealed a signiﬁcant
increase in the percentage of CD3(þ), CD4(þ), CD8(þ),
and CD56(þ) cells expressing perforin in allergic asthma
and a signiﬁcant increase inthe percentage of CD4(þ) and
CD56(þ) cells in intrinsic asthma when compared with
healthy control subjects. Perforin expression in CD4(þ)
cells in intrinsic asthma was also signiﬁcantly elevated
compared with allergic asthma. Thus,allergic andintrinsic
asthma is associated with increased expression of perforin
in T-lymphocyte subsets.
The responses to allergens are typically of the TH2
phenotype, with IL-4, IL-5, and IL-13 playing roles in IgE
isotype switching and eosinophil recruitment to the site of
inﬂammation. CD4þ CD25þ T cells have been shown to
regulate TH2 immune responses; however, their role in
control of allergic responses has yet to be deﬁned. TH1
cells exclusively produce IL-2 and IFN-g, and expression
of IL-1, IL-3, IL-10 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) are shared between TH1 and
TH2 subsets. TH1 subset, by virtue of IFN-g secretion,
confers a protective cell-mediated response to both
intracellular and extracellular bacterial pathogens. In this
case, IFN-g is required for the oxidative burst and
delayed-type. This type of response would be ineffectual
to pathogens such as helminthes because these large
organisms are resistant to phagocytosis and intracellular
oxidative bursts. Thus, TH2 cells in response to helminth
parasites mediate a protective type II response. In this
situation, TH2 secretion of IL-4 elicits B-cell production
of helminth antigen-speciﬁc IgE and secreted IgA, and
IL-5 induces the recruitment and activation of eosinophils
to sites of. Clearly, host-pathogen interactions have
provided a necessary selective pressure for the evolution
of TH subsets. Rheumatic diseases have divergent
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example exhibit TH2 tendency, while RA exhibit Th1
cytokine proﬁle. Atopic disorders are decreased in RA but
only slightly and non-signiﬁcantly increased in AS
(Rudwaleitetal.,2002).Thismayimplythatatopyconfers
someprotectionfromRAbutonlylittleifanysusceptibility
to AS. It may further indicate that the cytokine deviation
towards an impaired TH1 pattern in AS is less strong than
thecytokinedeviationtowardsTH1inRA,aﬁndingwhich
may affect future therapeutic approaches. There is a
signiﬁcantly lower incidence of allergic diseases in SLE
patients, especially those who have an allergic family
history, when comparedwith the controls (Sekigawa etal.,
2002).Theseﬁndingsmayberelatedtotheimmunological
similarities and differences between SLE and various
allergicdiseases.SuppressorTcellsplayimportantrolesin
the regulation of immune responses and the mediation of
dominant immunologic tolerance. Studies of suppressor
T-cell function were recently identiﬁed as a minor fraction
(approximately 10%) of CD4(þ) T cells that coexpress
CD25. CD4(þ) CD25(þ) T cells have been shown to
play a critical role in the prevention of organ- speciﬁc
autoimmunity and allograft rejection (McHugh and
Shevach, 2002). Because tumor antigens are self-antigens,
it is not surprising that CD4(þ) CD25(þ) T cells also
inhibit the induction of tumor immunity. Although
CD4(þ) CD25(þ) T cells are capable of inhibiting TH2
responses,theirroleinthesuppressionofallergicresponses
has not been ﬁrmly established. Depending on the desired
immune response, enhancement or restraint of suppressor
T-cell function might be required.
Because of the central role T cells play in immune
reactivity, the T-cell receptor (TCR) loci have long been
considered important candidates for common disease
susceptibility within the immune system such as asthma,
atopy, and autoimmunity.
Over the past two decades, hundreds of sequence
variations known as single nucleotide polymorphism
(SNPs) in the TCR loci have been identiﬁed. Most studies
have focused on deﬁning SNPs in the variable gene
segments which are involved in antigenic recognition. On
average, the coding sequence of each TCR variable gene
segment contains two SNPs, with many more found
in the 50,3 0 and intronic sequences of these segments
(Mackelprangetal.,2002).Meaningfulassociationstudies
intheTCRlociwillrequiretheanalysisandtypingoflarge
marker sets to fully evaluate the role of TCR loci in
common disease susceptibility in human populations.
Inherited abnormalities in either coding or regulatory
regions of TCR genes may predispose to aberrant T-cell
function and autoimmune disease (Kay, 1996).
CYTOKINE DYSREGULATION IN ALLERGIC
AND AUTOIMMUNE DISEASES
Multicellular organisms have three well-characterized
subfamilies of mitogen-activated protein kinases
(MAPKs) that control a vast array of physiological
processes (Johnson and Lapadat, 2002). These enzymes
are regulated by a characteristic phosphorelay system in
which a series of three protein kinases phosphorylate and
activate one another. The extracellular signal-regulated
kinases (ERKs) function in the control of cell division, and
inhibitors of these enzymes are being explored as
anticancer agents. The c-Jun amino-terminal kinases
(JNKs) are critical regulators of transcription, and JNK
inhibitors may be effective in control of RA. The p38
MAPKs are activated by inﬂammatory cytokines and
environmental stresses and may contribute to diseases like
asthma and autoimmunity.
GENETIC DETERMINANTS IN ALLERGY
ASTHMA AND AUTOIMMUNE DISEASES
The genetic basis of atopic diseases is represented by a
complex network of interacting genes or common genetic
variants rather than a few disease-causing mutations.
Polymorphism within IL-4R alpha, which is associated
with asthma and atopy, is also associated with kidney
systemic lupus erythematosus and Crohn’s disease
(Heinzmann and Deichmann, 2001). On the other hand,
there is a lower incidence or at least no increased risk of
allergic diseases in SLE patients, especially thosewho had
an allergic family histories, when compared with the
controls (Morton et al., 1998; Sekigawa et al., 2002).
CHRONIC URTICARIA AND AUTOIMMUNITY
Chronic urticaria deserves special consideration because
few elements may be invovled in its pathogenesis. Chronic
idiopathic urticaria (CIU) is a common and frustrating
disorder. A subset of patients with CIU has been classiﬁed
as autoimmune on the basis of two main ﬁndings:
association with thyroid autoimmunity and anti-IgE
and/or anti-IgE receptor antibodies (Leznoff et al.,
1983). CIU occurs in persons who do not have an
increased incidence of AD, allergic rhinitis, or asthma
compared with the incidence of these disorders in persons
without CIU. Their IgE level, as a group, is within normal
limits. CIU does not appear to be an allergic reaction in the
classic sense, because IgE antibody is not involved and no
external allergen is needed to initiate or perpetuate the
process. There is growing evidence that some cases of
CIU are associated with thyroid autoimmunity. Patients
with CIU have an increased frequency of Hashimoto
thyroiditis with the presence of antibodies to thyroglobu-
lin or a microsomal-derived antigen (peroxidase), even in
euthyroid patients. No broad non-speciﬁc autoimmunity is
present. Antibodies reactive with FceRI, the high-afﬁnity
IgE receptor are found in sera of 10–40% of patients with
CIU. A smaller subset of patients with CIU lack anti-
FceRI antibodies and have anti-IgE antibodies that cross-
link FceRIs occupied by IgE. There are minorities of CIU
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basophils by a serum factor that has not yet been
determined. Most patients with anti IgE antibodies have
an IgG antibody directed against the 34kD a subunit of
the IgE receptor. There are no data to suggest that any of
the anti thyroid antibodies is pathogenic in terms of CIU,
and most likely these are associated, parallel, autoimmune
events.
While the pathogenesis of CIU is not completely
understood, mast cell activation is thought to be of major
importance. Antibodies reactive with FceRI, the high-
afﬁnity IgE receptor, were found in sera of 10–40% of
patients with CIU (Gruber et al., 1988; Leznoff and
Sussman, 1989). These antibodies have the potential to
cross-link FceRIs on mast cells and basophils. This leads
to the release of mediators, chemokines, and cytokines.
A smaller subset of patients with CIU lack anti-FceRI
antibodies and have anti-IgE antibodies that cross-link
FceRIs occupied by IgE. Such antibodies were not speciﬁc
for CIU, however, and were detected in patients with AD.
A large number of patients with CIU have a positive
autologous skin test (Grattan et al., 1991). Most members
of subpopulation of positive patients studied in much
greater detail were found to have an IgG antibody directed
to the a subunit of the IgE receptor (Hide et al., 1993).
Patients with CIU and Hashimoto’s thyroiditis but not
patients without Hashimoto’s thyroiditis had anti-FceRI
antibodies in their sera that could induce degranulation of
normal basophils (Kandeel et al., 2001). Some sera from
patients with chronic urticaria and Hashimoto’s thyroiditis
caused degranulation of normal basophils in the absence
of anti-FceRI antibodies. The factor causing basophil
degranulation was not determined (Kandeel et al., 2001).
These results showed that Hashimoto’s thyroiditis likely
represents a marker of autoimmunity, rather than being a
direct cause for CIU. Immunoblot analysis demonstrated
that anti-IgE receptor antibodies bind to the 34-kD cloned
a subunit (Fiebiger et al., 1995). Recently a case of CIU
was described in association with Graves’ disease, where
anti FceRI antibodies were detected in addition to TSHR
antibodies (Irani et al., 2001). This report showed the
coexistence of these two conditions was mediated by a
different anti receptor antibody. Komiya et al. (2001)
analyzed the relationship between serum IgE concen-
trations and the remission or recurrence of Graves’
disease. Remission was found in 48.8% of patients with
elevated IgE concentrations after 18 months of treatment
with methimazole (MMI), as opposed to 80.3% of patients
with normal concentrations ðP ¼ 0:0014Þ: The rate of
long-standing remission was lower in patients with
elevated than normal IgE concentration (34.1 vs. 69.7%,
P ¼ 0:0007). Serum levels of interleukin (IL)-13 were
also analyzed. Although IL-13 was not detected in all
patients, the detection rate was higher in patients without
remission and in those with recurrence than in those with
long-standing remission ðP ¼ 0:0012Þ: Thus, the elevation
of IgE and the higher detection rate of IL-13 are associated
with both remission and recurrence of Graves’ disease.
Previous studies have found that 30–40% of hyper-
thyroid patients with Graves’ disease have an elevation of
serumIgEconcentrations($170IU/ml)(Satoetal.,1999).
In contrast, the prevalence of IgE elevation was
signiﬁcantly less in autoimmune Hashimoto’s thyroiditis
(Komiya et al., 2001). Interestingly, decreases in TSH-
binding inhibiting immunoglobulin (TBII) and thyroid-
stimulating antibody (TSAb) in response to antithyroid
drugs were less pronounced in patients with than without
IgE elevation (Sato et al., 1999). The role on IgE in
autoimmune Graves’ disease is not known. The most
plausible explanation is that IL-13 is secreted from Th-2
cells and has functions to stimulate B cells to secrete TBII,
TSAb, and IgE. Additional studies are required to conﬁrm
this concept. An elevation in IgE concentration is thought
to be linked with hereditary abnormalities (Hopkin, 1990;
Marsh, 1997). Human IL-4 operates through the IL-4
receptor (IL4R), thereby modulating IgE production and
Th-2 inﬂammatory reaction (Hakonarson et al., 1999). As
is the case with IL-4, IL-13 operates through the IL-13R to
stimulateIgEproductionandTh-2inﬂammatoryreactions.
Moreover, IL-13R and IL4R share a common component
in IL4Ra (Zurawski and de Vries, 1994) that is crucial for
IL-4 (or IL-13) binding and signal transduction de Vries,
1998. Gain-in-function mutations in IL4Ra have been
reportedtobeassociatedwithatopyorasthmapatientswith
elevated IgE concentrations (Khurana-Harshey et al.,
1997; Mitsuyasu et al., 1998). These might be present in
Graves’ patients with elevated IgE, even if peripheral
IL-13 or IL-4 were within normal range or not detected.
IMPLICATIONS FOR THERAPY—
IMMUNOMODULATION
Treatment of mast cells disease usually consists of anti
histamines and local application of glucocorticoids.
Future therapy potentially may include anti SCF
antibodies, directed against the main cytokine which
controls mast cell viability and survival (Table I).
Induction of long-term, antigen-speciﬁc immunologic
unresponsiveness holds great promise for the treatment of
many immune system-mediated diseases, including
asthma, allergies, autoimmune diseases, and transplant
rejection. Unlike current immunosuppressive treatments,
immunologic tolerance therapies would affect only the
undesired immune responses, leaving protective immunity
intact (Hackett and Dickler, 1999). A variety of
approaches to immunologic tolerance induction are
being taken, reﬂecting the molecular and cellular
complexity of immune system activation and regulation.
Possible approaches include the following: interference
with costimulatory signals in T-cell induction, TCR
antagonism by altered peptides, exploitation of antigen-
induced apoptosis to eliminate undesired T cells,
opposition of inﬂammation by the induction of regulatory
cytokines, induction of transplant tolerance by mixed
chimerism, and deviation from deleterious allergic
ALLERGYAND AUTOIMMUNITY 165antibody responses by use of immunostimulatory DNA
sequences. These multifaceted approaches are strongly
supported by knowledge of basic immune mechanisms,
which should facilitate the rational development of these
therapies for controlling immune-mediated diseases.
Therefore, immunologic or pharmacologic manipulation
of regulatory T-cell populations represents an important
future approach to immunotherapy of a wide range of
immune responses.
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